Welcome to our dedicated page for Zentalis Pharmaceuticals SEC filings (Ticker: ZNTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zentalis Pharmaceuticals, Inc. SEC filings document clinical oncology disclosures, financial results, governance matters and capital actions for the ZNTL public company. Recent Form 8-K filings cover azenosertib program updates, Regulation FD corporate presentations, clinical-trial and scientific-presentation exhibits, and results of operations furnished with business updates.
The company’s proxy materials describe board composition, executive compensation, equity awards and shareholder voting matters. Other event filings also record corporate governance changes and completed common stock repurchase activity, alongside cautionary risk language related to clinical development, regulatory pathways and forward-looking statements.
Zentalis Pharmaceuticals is advancing its WEE1 inhibitor azenosertib in platinum-resistant ovarian cancer by selecting 400mg once daily on a 5-days-on, 2-days-off schedule as the pivotal monotherapy dose for Cyclin E1-positive patients. This choice is based on a prespecified interim analysis from the DENALI Phase 2 Part 2a trial, which showed a clearly differentiated response rate versus 300mg with broadly comparable safety.
The 400mg QD 5:2 dose will be used across the registration-intended DENALI Phase 2 study and the confirmatory ASPENOVA Phase 3 trial, expected to initiate in Q2 2026 and enroll about 420 patients against investigator’s-choice chemotherapy. Zentalis plans a DENALI Part 2 topline readout by year-end 2026 and continues to target an accelerated approval pathway. In integrated datasets, azenosertib at 400mg QD 5:2 in Cyclin E1-positive PROC has shown objective response rates above 30% with median duration of response around five to six months, alongside a manageable safety profile. The company estimates roughly 21,500 Cyclin E1-positive PROC patients, about half of the PROC population, and reports $245 cash, cash equivalents and marketable securities as of December 31, 2025, which it believes can fund operations into late 2027.
Zentalis Pharmaceuticals is a clinical-stage biopharma company focused on developing azenosertib (ZN‑c3), an oral WEE1 inhibitor, primarily for Cyclin E1‑positive platinum‑resistant ovarian cancer (PROC). The company has no approved products and relies on external manufacturers and collaborators.
Azenosertib has shown single‑agent anti-tumor activity with objective response rates around one‑third in Cyclin E1‑positive PROC across multiple studies, using an intermittent 400 mg once‑daily 5:2 schedule. Zentalis believes the Phase 2 DENALI Part 2 study, if successful, could support accelerated U.S. approval, with the Phase 3 ASPENOVA trial planned as a confirmatory study.
The company highlights a sizable biomarker‑defined market opportunity in PROC and potential expansion into earlier ovarian cancer lines and other solid tumors. Key risks include continued losses, substantial capital needs, dependence on a single lead asset, complex regulatory pathways, competition from other WEE1 and oncology approaches, and reliance on third‑party manufacturers and CROs.
Zentalis Pharmaceuticals reported full-year 2025 results showing continued investment in its lead WEE1 inhibitor azenosertib while narrowing losses. The company ended 2025 with $245.9 million in cash, cash equivalents and marketable securities and expects this to fund operations into late 2027, beyond the planned DENALI Part 2 topline readout.
Revenue from licensing and intellectual property dropped to $0 in 2025 from $67.4 million in 2024, while net loss attributable to Zentalis improved to $137.1 million from $165.8 million. Research and development expenses declined to $107.3 million and general and administrative expenses to $37.7 million, reflecting sizable cost reductions and a restructuring charge of $7.8 million.
Clinically, Zentalis completed enrollment in DENALI Part 2a, aligned with the FDA on the Phase 3 ASPENOVA trial design, and is advancing the MUIR study of azenosertib plus bevacizumab in ovarian cancer. Key 2026 milestones include DENALI dose confirmation and Phase 3 ASPENOVA initiation in the first half of 2026, and DENALI Part 2 topline data by year-end, which could potentially support accelerated approval subject to FDA feedback.
Zentalis Pharmaceuticals, Inc. Schedule 13G reports that Squadron Master Fund LP (and related advisor and partners) beneficially hold 3,676,900 shares of common stock, representing 5.1% of the class.
The filing states this percentage is based on 72,250,779 shares outstanding as of November 1, 2025. The reporting persons disclose shared voting and shared dispositive power over the 3,676,900 shares and include a Rule 13d-4 disclaimer of beneficial ownership.
Zentalis Pharmaceuticals chief medical officer Ingmar Bruns reported automatic sales of company common stock to cover tax withholding on vested restricted stock units. On February 6, 2026, 2,962 shares were sold at $2.4297 per share, followed by 335 shares at $2.3929 per share on February 9, 2026. After these transactions, Bruns beneficially owned 33,332 shares of Zentalis common stock directly.
Zentalis Pharmaceuticals officer Vincent Vultaggio, who serves as PAO and PFO, reported several sales of company common stock. On February 6, 2026, he sold 29,951 shares at $2.4297 per share. On February 9, 2026, he sold 3,379 shares at $2.3929 per share, and on February 10, 2026, he sold 6,894 shares at $2.4223 per share. A footnote explains the first sale was made automatically by the company to cover tax withholding on vesting restricted stock units, while the later sale was executed under a pre-established Rule 10b5-1 trading plan. After these transactions, Vultaggio directly held 146,506 shares of Zentalis common stock.
Zentalis Pharmaceuticals, Inc. reported an insider transaction by its CEO & President and director, Julia Marie Eastland. On February 6, 2026, 7,866 shares of common stock were sold at $2.4297 per share, leaving 80,022 shares owned directly. On February 9, 2026, a further 889 shares were sold at $2.3929 per share, leaving 79,133 shares owned directly.
According to the footnote, these sales were made automatically by the issuer to cover tax withholding obligations arising from the vesting and settlement of restricted stock units previously granted to Eastland, rather than discretionary open-market sales.
Zentalis Pharmaceuticals officer Vincent Vultaggio reported two sales of common stock. On February 2, 2026, he sold 2,540 shares at $2.55 per share, an automatic sale by the company to cover tax withholding on vested restricted stock units.
On February 3, 2026, he sold 556 shares at $2.515 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he beneficially owned 186,730 shares of Zentalis common stock in direct form.
Zentalis Pharmaceuticals, Inc. reported that officer Vincent Vultaggio received a stock option grant for 100,000 shares on January 8, 2026. The options have an exercise price of $2.84 per share and expire on January 7, 2036. Following this grant, he beneficially owns 100,000 stock options directly.
According to the footnote, the options vest over four years in substantially equal monthly installments, and vesting depends on his continued service with the company. This structure ties the long-term value of the award to his ongoing tenure and the company’s future performance.
Zentalis Pharmaceuticals reported an equity award to its Chief Legal Officer, James B. Bucher. He received a stock option grant covering 100,000 shares of common stock at an exercise price of $2.84 per share. The options were granted on January 8, 2026 and are held directly. Following this grant, Bucher beneficially owns 100,000 stock options.
The options will vest over four years in substantially equal monthly installments, and vesting is conditioned on his continued service with the company. This is a compensatory award rather than an open-market purchase or sale.